Key issues include whether cervical cancer could benefit from TGF-β inhibition, whether a synergistic effect can be generated from combining TGF-β inhibition with RT, the choice of RT regimen (especially the RT dose) that maximizes efficacy, and the mechanisms involved is still to be addressed. Here, TGFB1 is linked to cervical carcinoma.